TG Therapeutics, Inc. (NASDAQ:TGTX) has been given an average rating of “Buy” by the twelve analysts that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and nine have assigned a buy rating to the company. The average 12 month price target among brokers that have updated their coverage on the stock in the last year is $26.86.
Several equities research analysts have recently issued reports on the stock. Zacks Investment Research cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 12th. ValuEngine cut shares of TG Therapeutics from a “hold” rating to a “sell” rating in a research report on Monday, October 16th. BidaskClub upgraded shares of TG Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 16th. Finally, SunTrust Banks, Inc. reiterated a “buy” rating and set a $28.00 price objective on shares of TG Therapeutics in a research report on Tuesday, October 3rd.
Shares of TG Therapeutics (NASDAQ TGTX) traded up 14.67% during trading on Wednesday, hitting $8.60. 2,699,506 shares of the stock were exchanged. The firm has a 50 day moving average of $11.41 and a 200-day moving average of $11.23. The stock’s market cap is $535.87 million. TG Therapeutics has a 52-week low of $4.10 and a 52-week high of $15.35.
TG Therapeutics (NASDAQ:TGTX) last released its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.46) by $0.01. The firm had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. TG Therapeutics had a negative net margin of 68,806.59% and a negative return on equity of 154.02%. Equities research analysts anticipate that TG Therapeutics will post ($1.84) earnings per share for the current fiscal year.
Institutional investors and hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. increased its position in TG Therapeutics by 44.0% in the second quarter. JPMorgan Chase & Co. now owns 364,025 shares of the biopharmaceutical company’s stock worth $3,658,000 after purchasing an additional 111,155 shares during the last quarter. Goldman Sachs Group Inc. increased its position in TG Therapeutics by 152.8% in the first quarter. Goldman Sachs Group Inc. now owns 43,020 shares of the biopharmaceutical company’s stock worth $501,000 after purchasing an additional 26,001 shares during the last quarter. Dupont Capital Management Corp bought a new stake in TG Therapeutics in the second quarter worth $258,000. Ameriprise Financial Inc. bought a new stake in TG Therapeutics in the first quarter worth $1,291,000. Finally, Russell Investments Group Ltd. bought a new stake in TG Therapeutics in the first quarter worth $811,000. Institutional investors own 49.86% of the company’s stock.
About TG Therapeutics
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.